The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 478 participants.
Also called NCT02536196
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Not applicable
- Enrolled
- 478 participants
- Sponsor
- Keystone Heart
- Registry
-
NCT02536196
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Germany, Italy, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT02536196. Randomized; single masking; primary purpose prevention. Start 2016-06 (actual); primary completion 2019-05 (actual). Results posted on 2021-02-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
- Condition
- Symptomatic Aortic Stenosis
- Intervention (Device)
- Embolic Protection Device
- Intervention (Procedure)
- Transcatheter aortic valve implantation (TAVI)
- Lead sponsor
- Keystone Heart
Record details
- Record id
cardio:ct-nct02536196- Content hash
de66af9d565520b0fb32b415df9a24c942e0c4b6b4f96b97b2689c02caad8166